(Q37842673)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21323768%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

review article

1 reference

title

Antiphospholipid syndrome: laboratory detection, mechanisms of action and treatment (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21323768%20AND%20SRC:MED&resulttype=core&format=json

antiphospholipid syndrome

22 January 2020

main subject

laboratory

0 references

1 reference

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21323768%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

author name string

A Tripodi

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21323768%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

P G de Groot

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21323768%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

language of work or name

English

0 references

publication date

11 March 2011

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21323768%20AND%20SRC:MED&resulttype=core&format=json

Journal of Internal Medicine

22 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21323768%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

volume

270

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21323768%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21323768%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

page(s)

110-122

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21323768%20AND%20SRC:MED&resulttype=core&format=json

International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS)

22 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2011.02362.X

Anticardiolipin antibodies: detection by radioimmunoassay and association with thrombosis in systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2011.02362.X

Special report. The Second International Anti-cardiolipin Standardization Workshop/the Kingston Anti-Phospholipid Antibody Study (KAPS) group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2011.02362.X

Anticardiolipin wet workshop report. Fifth International Symposium on antiphospholipid antibodies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2011.02362.X

Interlaboratory inconsistencies in detection of anticardiolipin antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2011.02362.X

Antiphospholipid antibody ELISAs: survey on the performance of clinical laboratories assessed by using lyophilized affinity-purified IgG with anticardiolipin and anti-beta2-Glycoprotein I activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2011.02362.X

Laboratory testing for lupus anticoagulants: diagnostic criteria and use of screening, mixing, and confirmatory studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2011.02362.X

Update of the guidelines for lupus anticoagulant detection. Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2011.02362.X

Lupus anticoagulants and their relationship with the inhibitors against coagulation factor VIII: considerations on the differentiation between the 2 circulating anticoagulants

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2011.02362.X

Thrombogenicity of beta 2-glycoprotein I-dependent antiphospholipid antibodies in a photochemically induced thrombosis model in the hamster

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2011.02362.X

Antiphospholipid antibodies and the antiphospholipid syndrome: pathogenic mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2011.02362.X

Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2011.02362.X

International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2011.02362.X

beta2-glycoprotein I-dependent lupus anticoagulant highly correlates with thrombosis in the antiphospholipid syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2011.02362.X

Adhesion mechanism of human beta(2)-glycoprotein I to phospholipids based on its crystal structure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2011.02362.X

Beta2-glycoprotein I can exist in 2 conformations: implications for our understanding of the antiphospholipid syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2011.02362.X

Autoantibodies against EPCR are found in antiphospholipid syndrome and are a risk factor for fetal death

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2011.02362.X

Beta2-glycoprotein I binds thrombin via exosite I and exosite II: anti-beta2-glycoprotein I antibodies potentiate the inhibitory effect of beta2-glycoprotein I on thrombin-mediated factor XIa generation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2011.02362.X

Antibodies to factor XII and recurrent fetal loss in patients with the anti-phospholipid syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2011.02362.X

Beta2-glycoprotein I protects thrombin from inhibition by heparin cofactor II: potentiation of this effect in the presence of anti-beta2-glycoprotein I autoantibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2011.02362.X

Correlation between antiphospholipid antibodies that recognize domain I of beta2-glycoprotein I and a reduction in the anticoagulant activity of annexin A5.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2011.02362.X

Pregnancy loss in the antiphospholipid-antibody syndrome--a possible thrombogenic mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2011.02362.X

Annexin A5 is not essential for skeletal development

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2011.02362.X

Antibodies to tissue-type plasminogen activator (tPA) in patients with antiphospholipid syndrome: evidence of interaction between the antibodies and the catalytic domain of tPA in 2 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2011.02362.X

Autoantibodies against the fibrinolytic receptor, annexin 2, in antiphospholipid syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2011.02362.X

Complement C3 activation is required for antiphospholipid antibody-induced fetal loss

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2011.02362.X

Complement C5a receptors and neutrophils mediate fetal injury in the antiphospholipid syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2011.02362.X

Tissue factor: a link between C5a and neutrophil activation in antiphospholipid antibody induced fetal injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2011.02362.X

Atypical hemolytic-uremic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2011.02362.X

Interaction of beta2-glycoprotein I with members of the low density lipoprotein receptor family.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2011.02362.X

{beta}2 Glycoprotein I ({beta}2GPI) binds platelet factor 4 (PF4): implications for the pathogenesis of antiphospholipid syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2011.02362.X

Role of the MyD88 transduction signaling pathway in endothelial activation by antiphospholipid antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2011.02362.X

Endothelial function is impaired in patients with primary antiphospholipid syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2011.02362.X

A systematic review of secondary thromboprophylaxis in patients with antiphospholipid antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2011.02362.X

A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2011.02362.X

A randomized clinical trial of high-intensity warfarin vs. conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome (WAPS)

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2011.02362.X

Clinical course of high-risk patients diagnosed with antiphospholipid syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2011.02362.X

Lowering the intensity of oral anticoagulant therapy: effects on the risk of hemorrhage and thromboembolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2011.02362.X

Anticardiolipin antibodies predict early recurrence of thromboembolism and death among patients with venous thromboembolism following anticoagulant therapy. Duration of Anticoagulation Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2011.02362.X

Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2011.02362.X

Residual thrombosis on ultrasonography to guide the duration of anticoagulation in patients with deep venous thrombosis: a randomized trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2011.02362.X

D-dimer testing to determine the duration of anticoagulation therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2011.02362.X

Antiphospholipid antibodies and subsequent thrombo-occlusive events in patients with ischemic stroke

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2011.02362.X

Antithrombotic and thrombolytic therapy for ischemic stroke: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2011.02362.X

Warfarin, aspirin, or both after myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2011.02362.X

Aspirin and coumadin after acute coronary syndromes (the ASPECT-2 study): a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2011.02362.X

Randomised controlled trial of aspirin and aspirin plus heparin in pregnant women with recurrent miscarriage associated with phospholipid antibodies (or antiphospholipid antibodies)

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2011.02362.X

Antiphospholipid syndrome in pregnancy: a randomized, controlled trial of treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2011.02362.X

Treatment of pregnant patients with antiphospholipid syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2011.02362.X

Management of thrombosis in antiphospholipid syndrome and systemic lupus erythematosus in pregnancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2011.02362.X

Plasma exchange in the management of high risk pregnant patients with primary antiphospholipid syndrome. A report of 9 cases and a review of the literature.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2011.02362.X

Catastrophic antiphospholipid syndrome: international consensus statement on classification criteria and treatment guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2011.02362.X

Catastrophic antiphospholipid syndrome: where do we stand?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2011.02362.X

Recovery from catastrophic antiphospholipid syndrome by a plasma exchange procedure: report of four cases and review of the literature.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2011.02362.X

Use of rituximab in the antiphospholipid syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2011.02362.X

Clinical significance of different antiphospholipid antibodies in the WAPS (warfarin in the antiphospholipid syndrome) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2011.02362.X

Do antibodies to beta2-glycoprotein 1 contribute to the better characterization of the antiphospholipid syndrome?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2011.02362.X

Does the anti-beta2-glycoprotein I antibody provide additional information in patients with thrombosis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2011.02362.X

The presence of IgG antibodies against beta2-glycoprotein I predicts the risk of thrombosis in patients with the lupus anticoagulant.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2011.02362.X

beta2-Glycoprotein I inhibits von Willebrand factor dependent platelet adhesion and aggregation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2011.02362.X

The immunology of atherothrombosis in the antiphospholipid syndrome: antigen presentation and lipid intracellular accumulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2011.02362.X

Usefulness of repeated D-dimer testing after stopping anticoagulation for a first episode of unprovoked venous thromboembolism: the PROLONG II prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2011.02362.X

Anti–β2-glycoprotein I antibodies induce monocyte release of tumor necrosis factor α and tissue factor by signal transduction pathways involving lipid rafts

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2011.02362.X